NCCN Flash Updates: NCCN Templates^® Updated for Prostate Cancer, Kidney Cancer, Occult Primary Cancer, and Ovarian Cancer

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Prostate Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Prostate Cancer v2.2020.

• The following NEW NCCN Templates^® have been published:
  • PRO10: DOCEtaxel
  • PRO24: Olaparib
  • PRO25: Rucaparib
• Changes to the Chemotherapy Regimen section have been made to the following templates:
  • PRO1: CARBOplatin/Etoposide
  • PRO2: CISplatin/Etoposide
  • PRO4: DOCEtaxel/PredniSONE
  • PRO7: CABAZItaxel/PredniSONE
  • PRO8: Abiraterone/PredniSONE or MethylPREDNISolone
  • PRO12: Pembrolizumab
  • PRO13: Goserelin
  • PRO14: Histrelin
  • PRO15: Leuprolide
  • PRO16: Triptorelin
  • PRO17: Degarelix
  • PRO18: Nilutamide
  • PRO19: Flutamide
  • PRO20: Bicalutamide
• Changes to the Indication section have been made to the following templates:
  • PRO4: DOCEtaxel/PredniSONE
  • PRO7: CABAZItaxel/PredniSONE
  • PRO9: Enzalutamide
  • PRO21: Apalutamide
  • PRO22: Darolutamide
• References have been updated on the following templates:
  • PRO1: CARBOplatin/Etoposide
  • PRO2: CISplatin/Etoposide
  • PRO4: DOCEtaxel/PredniSONE
  • PRO7: CABAZItaxel/PredniSONE
  • PRO8: Abiraterone/PredniSONE or MethylPREDNISolone
  • PRO9: Enzalutamide
  • PRO11: DOCEtaxel/CARBOplatin
  • PRO12: Pembrolizumab
  • PRO21: Apalutamide
• Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • Apalutamide
  • Bicalutamide
  • CABAZItaxel
  • CISplatin
  • Degarelix
  • DOCEtaxel
  • Etoposide
  • Flutamide
  • Goserelin
  • Histrelin
  • Leuprolide
  • Nilutamide
  • Triptorelin

NCCN has published updates to the NCCN Templates for Kidney Cancer to reflect the currently published NCCN Guidelines^® for Kidney Cancer v2.2020.

• Changes to the Chemotherapy Regimen section have been made to the following templates:
  • KDN30-Axitinib + Pembrolizumab
• References have been updated on the following template:
  • KDN30-Axitinib + Pembrolizumab

NCCN has published updates to the NCCN Templates for Occult Primary Cancer to reflect the currently published NCCN Guidelines for Occult Primary Cancer v3.2020.

• Changes to the Chemotherapy Regimen section have been made to the following template:
  • OCP20-Pembrolizumab
• References have been updated on the following template:
  • OCP20-Pembrolizumab

NCCN has published updates to the NCCN Templates for Ovarian Cancer to reflect the currently published NCCN Guidelines for Ovarian Cancer v1.2020.

• The following NEW NCCN Templates have been published:
  • OVA74-Olaparib + Bevacizumab
  • OVSCST9-CISplatin/Etoposide
  • OVSCST10-Anastrozole
  • OVSCST11-Exemestane
  • OVSCST12-Letrozole
  • OVSCST13-Tamoxifen
• Changes to the Indication section have been made to the following template:
  • OVA29-Pembrolizumab
• Changes to the Chemotherapy Regimen section have been made to the following template:
  • OVA29-Pembrolizumab
• References have been updated on the following template:
  • OVA29- Pembrolizumab

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please note: The NCCN Third Party Content FTP site: ftp://ftp1.nccn.org/ThirdPartyContent/ has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.